Key points
- Revenues from ordinary activities increased by 384,707
- Loss from ordinary activities after tax decreased by 36.0% to (5,632,977)
- Secured an expanded global license for PhotosoftTM technology
Full summary
Invion Ltd's annual report for FY26 shows a loss of $5.6 million, down from $8.8 million in FY25. The company reported an increase in revenues from ordinary activities to $384,707. Invion made significant progress in its clinical and pre-clinical programs, secured an expanded global license for its PhotosoftTM technology, and received a non-dilutive funding arrangement from the South Korean government. The company also achieved Orphan Drug Designation for INV043 in the treatment of anal cancer and expanded its INV043 clinical trial program for non-melanoma skin cancer.
Guidance
FY26 loss from ordinary activities after tax: $5,632,977
Outlook
Invion is optimistic about the future of its PhotosoftTM technology and its potential to treat various cancers and diseases. The company is exploring new partnerships and funding opportunities to further its research and development efforts.